Los Angeles, USA, April 26, 2021 (GLOBE NEWSWIRE) -- Atrial Fibrillation Pipeline Drugs and Companies Insight Report: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
The global demand for Atrial Fibrillation treatment options is emerging swiftly, driven by consumption in major emerging markets. As more growth opportunities will surge, several companies such as ARCA biopharma, AbbVie, Hanmi Pharmaceutical, Espero BioPharma, Vivasc Therapeutics, HUYA Bioscience, Novartis, Acesion Pharma, and others are working on Atrial Fibrillation pipeline.
DelveInsight’s “Atrial Fibrillation Pipeline Insight” report provides comprehensive insights about 17+ companies and 17+ pipeline drugs in the Atrial Fibrillation pipeline landscapes. It comprises Atrial Fibrillation pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Atrial Fibrillation therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Atrial Fibrillation pipeline products.
Some of the key takeaways of the Atrial Fibrillation Pipeline Report
- In March 2021, Milestone Pharmaceuticals announced the first patient had been enrolled in its Phase II proof-of-concept study of etripamil nasal spray to reduce Ventricular Rate in patients experiencing AF and rapid ventricular rate (AFib-RVR), or the ReVeRA study.
- AGN-151607 is an inhibitor of acetylcholine, a modulator of membrane transport protein and acts as neuromuscular blocking agents. Allergan initially developed it.
- In May 2020, AbbVie announced that it had completed its acquisition of Allergan plc following receipt of regulatory approval from all government authorities required by the transaction agreement and acceptance by the Irish High Court.
- In February 2020, HUYA Bioscience International announced the successful completion of Phase I Trial of HBI-3000.
- Currently, Abbvie is developing AGN-151607 and is in the phase II stage of development for Atrial Fibrillation treatment.
Get an overview of pipeline landscape @ Atrial Fibrillation Clinical Trials Analysis
Atrial Fibrillation is an irregular heartbeat that can lead to blood clots, stroke, heart failure and other heart-related complications. The atria beat chaotically and irregularly out of coordination with the ventricles of the heart.
Atrial Fibrillation Emerging Drugs
- Etripamil: Milestone Pharmaceuticals
Etripamil, the lead investigational product, is developed to be a rapid-response therapy for episodic cardiovascular conditions. The novel calcium channel blocker is self-administered through a nasal spray that may shift the current treatment paradigm for many patients with Paroxysmal supraventricular tachycardia (PSVT) in the emergency department to the at-home setting. Milestone is conducting a thorough development program for etripamil, with Phase 3 trials underway in PSVT, and intends to start a Phase 2 proof-of-concept trial in patients with atrial fibrillation with rapid ventricular rate, with subsequent studies anticipated in other conditions where calcium channel blockers are utilised.
- OMT 28: OMEICOS Therapeutics
OMT-28 is a stable synthetic small molecule analogue of the natural omega-3 fatty acid metabolite 17, 18-EEQ, which has a structure optimised to confer efficacy, safety, and oral availability. The compound has shown its anti-arrhythmic, cardioprotective, and anti-fibrotic potential in different in vivo models. Presently, it is in phase 2 of clinical trials for the Atrial Fibrillation treatment.
- HBI-3000 (sulcardine sulfate trihydrate): HUYA Bioscience International
HBI-3000 is a multi-ion channel blocker with effects on INa-Peak, INa-Late, ICa, L, and IKr with similar in vitro potencies across these several ion channels in human atrial cardiomyocytes. It is being developed by HUYA Bioscience International® (HUYABIO™) for the conversion of recent-onset Atrial Fibrillation. It is currently undergoing phase 1 of clinical trials.
- AP 30663: Acesion Pharma
It is based on the inhibition of SK channels - ion channels present in the atria that regulate the cardiac rhythm. Inhibiting these ion channels with a functionally atrial selective drug help avoid harmful effects on the ventricles. Targeting the SK channels thereby comprises a novel and promising approach for an effective treatment for Atrial Fibrillation with an anticipated higher safety and tolerability profile.
For further information, refer to the detailed report @ Atrial Fibrillation Pipeline Therapeutics
Scope of Atrial Fibrillation Pipeline Drug Insight
- Coverage: Global
- Major Players: 17+ Key Players
- Prominent Players: ARCA biopharma, AbbVie, Espero BioPharma, Vivasc Therapeutics, Hanmi Pharmaceutical, HUYA Bioscience, Novartis, Acesion Pharma, and many others.
- Key Drugs Profiles: 17+ Products
- Phases:
- Mechanism of Action:
- Beta 1 adrenergic receptor antagonists
- Ion channel antagonists
- Acetylcholine inhibitors
- KATP channel inhibitors; Sodium channel antagonists
- Molecule Types:
- Small molecules
- Natural metabolites
- Monoclonal antibodies
- Route of Administration:
- Subcutaneous
- Intravenous
- Oral
- Intramuscular
- Product Types:
- Monotherapy
- Combination
- Mono/Combination
-
- Atrial Fibrillation Therapies Late-stage (Phase III)
- Atrial Fibrillation Therapies Mid-stage (Phase II)
- Atrial Fibrillation Therapies Early-stage (Phase I)
- Atrial Fibrillation Pre-clinical stage and Discovery candidates
- Discontinued and Inactive candidates
- Mechanism of Action:
Key Questions regarding Current Atrial Fibrillation Treatment Landscape and Emerging Therapies Answered in the Pipeline Report
- What are the current options for Atrial Fibrillation treatment?
- How many companies are developing therapies for the treatment of Atrial Fibrillation?
- How many are Atrial Fibrillation emerging therapies in the early-stage, mid-stage, and late development stages to treat Atrial Fibrillation?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and significant licensing activities that will impact the Atrial Fibrillation market?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies for the treatment of Atrial Fibrillation?
- What are the current novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing Atrial Fibrillation therapies?
- What are the critical designations that have been granted for the emerging therapies for Atrial Fibrillation?
- How many patents are granted and pending for the emerging therapies to treat Atrial Fibrillation?
Table of Contents
| 1 | Atrial Fibrillation Report Introduction |
| 2 | Atrial Fibrillation Executive Summary |
| 3 | Atrial Fibrillation Overview |
| 4 | Atrial Fibrillation- Analytical Perspective In-depth Commercial Assessment |
| 5 | Atrial Fibrillation Pipeline Therapeutics |
| 6 | Atrial Fibrillation Late Stage Products (Phase II/III) |
| 6.1 | Gencaro: ARCA biopharma |
| 7 | Atrial Fibrillation Mid Stage Products (Phase II) |
| 7.1 | AGN-151607:AbbVie |
| 8 | Atrial Fibrillation Early Stage Products (Phase I) |
| 8.1 | HIP-2001: Hanmi Pharmaceutical |
| 9 | Atrial Fibrillation Preclinical Stage Products |
| 9.1 | ESP-001:Espero BioPharma |
| 10 | Atrial Fibrillation Therapeutic Assessment |
| 11 | Atrial Fibrillation Inactive Products |
| 12 | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13 | Atrial Fibrillation Key Companies |
| 14 | Atrial Fibrillation Key Products |
| 15 | Atrial Fibrillation Unmet Needs |
| 16 | Atrial Fibrillation Market Drivers and Barriers |
| 17 | Atrial Fibrillation Future Perspectives and Conclusion |
| 18 | Atrial Fibrillation Analyst Views |
| 19 | Appendix |
| 20 | About DelveInsight |
Get a customised pipeline report @ Atrial Fibrillation Drugs Pipeline Report
Related Reports
DelveInsight's Atrial Fibrillation - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Atrial Fibrillation - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Atrial Fibrillation in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
DelveInsight’s Atrial Flutter Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight's Cystic fibrosis - Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
DelveInsight’s Fibrocystic Breast Condition Market Insights, Epidemiology and Market Forecast - 2030 report provides a detailed overview of the disease and a depth understanding of historical and forecasted epidemiology.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also proffers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.